Utilizing ulcerative colitis and apical periodontitis as disease models, we found that CXCR4/Cur‐CMVs could effectively target inflammation sites in vivo and significantly ameliorate the inflammatory symptoms of ulcerative colitis and apical periodontitis, thus suggesting that CMVs with enriched display of membrane CXCR4 might be a promising inflammation‐targeting delivery system for inflammatory disease treatment. The gene discussed is CXCR4; the disease is periapical periodontitis.